The EHRs did not record RF evolution, TDM requests and results or PIs in 53 (70%), 23 (30%), 39 (51%) and 61 (80%) cases respectively.

Conclusions The low percentage recording of TDM-related variables and pharmacist interventions in EHR potentially limits inter-professional communication and the decision-making process. This fact highlights the need for clinical pharmacists to safeguard the information they have discovered by recording their interventions in the EHR as a clinical episode in comprehensive patient care. This will increase the visibility of the pharmacist and the effect of his/her actions.

No conflict of interest.

USE OF ELECTROENCEPHALOGRAPHY (EEG)-BASED METRICS TO TEST THE GUSTATORY PROPERTIES OF LIQUID TRIMETHOPRIM FORMULATIONS

P Almeida, P Chaves, P Carinha, P Barata, D Santos. University of Porto, Laboratory of Neurophysiopsychology, Porto, Portugal; Centro Hospital S Joao, Serviços Farmacêuticos, Porto, Portugal; Faculdade Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal; Faculdade Farmácia, Universidade Porto, Porto, Portugal

Background It is well known that the gustatory properties of a formulation strongly affect patient adherence to a treatment. However, measuring these properties is highly subjective and difficult, especially for the paediatric population. The use of neurophysiological and covert behaviours in assessing the attractive properties of sensorial stimuli has a long tradition in the domain of affective neuroscience. Ways of measuring range from the use of autonomous nervous system activation patterns, to features extracted from electroencephalographic activity or simple and discriminative reaction time tasks. These measurements provide alternative means for assessing the characteristics of commercial products, overcoming the limitations of self-reporting-based research, namely social desirability, and for studying populations unable to provide usable verbal responses (e.g. children). The EHRs did not record RF evolution, TDM requests and results or PIs in 53 (70%), 23 (30%), 39 (51%) and 61 (80%) cases respectively.

Purpose To find out if this methodology can be used for evaluating the gustatory properties of formulations in order to enhance patient adherence.

Materials and Methods Trimethoprim formulations were prepared using NF syrup. Flavour was added afterwards. Participants were stimulated with 3 different flavoured formulations (banana, red berry and neutral) for 10 seconds each while subjected to an EEG recording. The order of presentation was fully counter-balanced between subjects. Subjects rated the different solutions for palatability and intensity. Five seconds of the EEG response for each sample was converted to the frequency domain, and the log power and inter-hemispheric asymmetry were calculated for anterior, central and parietal electrodes. Different algorithms, combining different EEG features, were tested for predictive power regarding palatability and type of formula.

Results Theta inter-hemispheric activity at parietal electrodes predicted the behavioural assessment of palatability (R2 = 0.85). Moreover, the application of unsupervised learning methods, such as Support Vector Machines, on the log power at different bands from 0 to 12 Hz, could distinguish with up to 95.24% accuracy between flavoured and non-altered solutions.

Conclusions This technology can be used in formulation studies that are attempting to enhance the organoleptic properties of a formulation.

No conflict of interest.

VALIDATION OF AN AUTOMATED COMPOUNDER SET UP ONCE A WEEK FOR PARENTERAL NUTRITION SOLUTIONS

L Bouchoud, F Sadeghipour, S Fleury, P Bonnabry. University Hospitals of Geneva, Pharmacy, Geneva, Switzerland

Background Our parenteral nutrition production (PN) decreased after we introduced standard solutions. To keep just a small number of daily PN items cost-effective, we decided to validate a once a week setting up of an automated compounding device (ACD).

Purpose To test the operation and performance of an ACD (Baxa MM12) for a once a day and a once a week use.

Materials and Methods Accuracy (mean in % of the expected value) and precision (Coefficient of Variation) of the ACD was evaluated by weighing different volumes of water 10 times (0.5 to 40 mL; daily operational qualification) and different volumes of different parental preparations to be prepared in the ACD.

Results The operation of the ACD was found to be satisfactory. The validation of the device was performed in 3 different weeks with 40, 40 and 25 batches of each final formulation. Samples were stored at 5 ± 3°C (light exposed and protected) and at 22 ± 3°C (light exposed and protected) and 40 ± 2°C/75 ± 5% RH for 98 days (samples collected at 6 time points). Organoleptic characteristics, pH, viscosity, MH and preservative content were assessed. Sterility tests, microbiological control and preservative efficacy were studied according to Ph. Eur. The MH release profile was evaluated using Franz cells.

Conclusions The MH gels presented suitable physicochemical and pharmaceutical characteristics for topical application to painful wounds. The slow release profile may reduce the number of applications.

No conflict of interest.
Drugs supply/logistics

nutrients (0.5 to 100 mL, daily performance qualification) over 3 consecutive days. The concentration of nutrients (glucose, Na and K) in PN, particulate contamination and media-fill tests were checked each day while the machine’s settings were only adjusted once a week (3 consecutive weeks). Some bottles were changed during the week and other remained in place, according to a predefined protocol. The ACD was installed in a laminar airflow hood GMP Class A with a cleanroom Class B background and a temperature around 20°C.

Results Daily operational and performance results:

<table>
<thead>
<tr>
<th></th>
<th>0.5 mL</th>
<th>40 mL</th>
<th>100 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Accuracy</td>
<td>Precision</td>
<td>Accuracy</td>
</tr>
<tr>
<td>Water</td>
<td>100.9%</td>
<td>3.2%</td>
<td>98.9%</td>
</tr>
<tr>
<td>Nutrient</td>
<td>99.3–102.7%</td>
<td>2.7–3.9%</td>
<td>99.9%</td>
</tr>
</tbody>
</table>

* Depending on nutrient

The concentrations of nutrients in PN products made weekly always met the specifications (internal limits ±15% for Na, ±10% for glucose and –15% to +10% for K). No particles or microbiological contamination were detected.

Conclusions Validation proved the acceptable accuracy, precision and aseptic conditions in the course of the week. A sepsis can only be guaranteed by a strict application of GMP in a high-quality compound environment. In those conditions, PN products can be produced safely for one week with the same settings. Setting it just once a week saves technician time (300 hours/year) and money (15,000 Euro/year).

No conflict of interest.

Drug supply/logistics (including: computer-aided drug dispatching and ward pharmacies)

[DSL-001] A MULTIDISCIPLINARY APPROACH TO FURTHER IMPROVEMENTS IN PATIENT SAFETY IN A HOSPITAL WITH COMPUTERISED MEDICAL RECORDS

doi:10.1136/ehjp-2013-000276.244

C Cuesta-Grueno, J Poquet-Jornet, E Flores-Pardo, C Santos-Ramírez, A Pacios-Alvarez, MJ Mass-Llull. 1Hospital de Denia, Pharmacy, Denia, Spain; 2Hospital de Denia, Quality, Denia, Spain; 3Hospital de Denia, Rheumatology, Denia, Spain; 4Hospital de Denia, Hematology, Denia, Spain; 5Hospital de Denia, nursing supervisor, Denia, Spain

Background Antineoplastic treatments administered at the Medical Day Hospital Unit (MDHU) are high risk for the patient because of their toxicity and mutagenicity and complex pharmacotherapeutic processes. In our hospital medical records are fully computerised and all prescriptions are electronic. So, it is desirable to standardise criteria in a consensus document that minimises variability among professionals to maximise the safety and clinical effectiveness for oncology patients.

Purpose To identify the key points of information that should appear in the consensus document to ensure the correct administration of antineoplastic treatments.

Materials and Methods A multidisciplinary group was created (two physicians, one pharmacist, one nurse and quality mangers). The initial criteria for determining the key points to be imparted were patient safety, clinical effectiveness, organisational coordination and traceability in the Information System. These criteria led to the establishment of 12 key points of information to develop a standard operating procedure (SOP) for each antineoplastic treatment.

Results The 12 key points that were agreed to establish SOPs for each treatment were: indications and usage; prescription form in the Electronic Health Record; pharmaceutical validation to ensure correct indication, dose, volume and type of diluent and infusion time; general and specific nursing indications; contraindications; monitoring of vital signs and anthropometric measures necessary; premedication and time spent on it; preparation of the medicine; possible adverse reactions to the infusion and their management; causes of suspension of treatment; patient information; responsibilities of each professional.

Conclusions The development of SOPs to standardise the pharmacotherapeutic process in the MDHU contribute to improving the safety and efficiency of antineoplastic treatments. In addition, in a hospital with medical records and where all prescribing is electronic, SOPs contributes to improving the organisation of a complex nursing unit such as the MDHU.

No conflict of interest.